[go: up one dir, main page]

WO2009007675A3 - Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires - Google Patents

Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires Download PDF

Info

Publication number
WO2009007675A3
WO2009007675A3 PCT/GB2008/002201 GB2008002201W WO2009007675A3 WO 2009007675 A3 WO2009007675 A3 WO 2009007675A3 GB 2008002201 W GB2008002201 W GB 2008002201W WO 2009007675 A3 WO2009007675 A3 WO 2009007675A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
antagonist
mast cell
gamma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/002201
Other languages
English (en)
Other versions
WO2009007675A2 (fr
Inventor
Johan Raud
Carl-Johan Dalsgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardoz AB
Original Assignee
Cardoz AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz AB filed Critical Cardoz AB
Publication of WO2009007675A2 publication Critical patent/WO2009007675A2/fr
Publication of WO2009007675A3 publication Critical patent/WO2009007675A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des produits d'association comprenant (a) un inhibiteur de mastocyte, ou un sel ou solvate pharmaceutiquement acceptable de celui-ci; et (b) un antagoniste P2Y12, ou un sel ou solvate pharmaceutiquement acceptable de celui-ci. De tels produits d'association ont une utilité particulière dans le traitement de l'athérosclérose et d'états apparentés.
PCT/GB2008/002201 2007-07-11 2008-06-25 Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires Ceased WO2009007675A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92972907P 2007-07-11 2007-07-11
US92973207P 2007-07-11 2007-07-11
US60/929,732 2007-07-11
US60/929,729 2007-07-11

Publications (2)

Publication Number Publication Date
WO2009007675A2 WO2009007675A2 (fr) 2009-01-15
WO2009007675A3 true WO2009007675A3 (fr) 2009-03-12

Family

ID=39769186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002201 Ceased WO2009007675A2 (fr) 2007-07-11 2008-06-25 Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires

Country Status (1)

Country Link
WO (1) WO2009007675A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
JP2012528844A (ja) * 2009-06-01 2012-11-15 バイオコピア リミテッド 好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用
JPWO2011065444A1 (ja) * 2009-11-27 2013-04-18 学校法人東海大学 抗血栓剤
WO2011076749A2 (fr) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Forme solide de dosage pharmaceutique
EP2377520A1 (fr) * 2010-03-24 2011-10-19 Ratiopharm GmbH Composition pharmaceutique du prasugrel
GB201601138D0 (en) * 2016-01-21 2016-03-09 Rspr Pharma Ab New use
CN109646442B (zh) * 2019-01-29 2023-01-24 军事科学院军事医学研究院生物医学分析中心 乙酸酯类化合物在制备环鸟腺苷合成酶乙酰化药物中的用途
CN116747304B (zh) * 2023-05-09 2025-10-28 浙江大学 P2y12受体及其拮抗剂的用途
WO2025159459A1 (fr) * 2024-01-25 2025-07-31 재단법인대구경북과학기술원 Composition pharmaceutique pour la prévention ou le traitement de maladies cérébrales dégénératives, comprenant du prasugrel en tant que principe actif

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
EP0316174A1 (fr) * 1987-11-10 1989-05-17 Tokyo Tanabe Company Limited Préparation aqueuse du sel de potassium du 9-méthyle-3-(1H-tétrazol-5-yle)-4H-pyrido[1,2-a]-pyrimidine-4-one
EP0766963A1 (fr) * 1994-05-31 1997-04-09 Tokyo Tanabe Company Limited Depresseur de l'arteriosclerose
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
EP1285921A1 (fr) * 2001-08-10 2003-02-26 Dinamite Dipharma S.p.A. Procédé de la fabrication de pemirolast pure
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US20050181023A1 (en) * 2004-02-17 2005-08-18 Young Janel E. Drug-enhanced adhesion prevention
WO2005092264A1 (fr) * 2004-03-10 2005-10-06 Ethicon, Inc. Prevention des adherences amelioree par des medicaments
WO2007024472A2 (fr) * 2005-08-19 2007-03-01 Eli Lilly And Company Procede pour le traitement de maladies vasculaires

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
EP0316174A1 (fr) * 1987-11-10 1989-05-17 Tokyo Tanabe Company Limited Préparation aqueuse du sel de potassium du 9-méthyle-3-(1H-tétrazol-5-yle)-4H-pyrido[1,2-a]-pyrimidine-4-one
EP0766963A1 (fr) * 1994-05-31 1997-04-09 Tokyo Tanabe Company Limited Depresseur de l'arteriosclerose
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
EP1285921A1 (fr) * 2001-08-10 2003-02-26 Dinamite Dipharma S.p.A. Procédé de la fabrication de pemirolast pure
US20050181023A1 (en) * 2004-02-17 2005-08-18 Young Janel E. Drug-enhanced adhesion prevention
WO2005092264A1 (fr) * 2004-03-10 2005-10-06 Ethicon, Inc. Prevention des adherences amelioree par des medicaments
WO2007024472A2 (fr) * 2005-08-19 2007-03-01 Eli Lilly And Company Procede pour le traitement de maladies vasculaires

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"PEMIROLAST POTASSIUM", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 28, no. 1, 1 January 1992 (1992-01-01), pages 29 - 31, XP008066535, ISSN: 0025-7656 *
ISAJI M ET AL: "TRANILAST INHIBITS THE PROLIFERATION, CHEMOTAXIS AND TUBE FORMATIONOF HUMAN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO AND ANGIOGENESIS IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 122, no. 6, November 1997 (1997-11-01), pages 1061 - 1066, XP000997892, ISSN: 0007-1188 *
JONES N L ET AL: "Ketotifen therapy for acute ulcerative colitis in children: A pilot study", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 3, March 1998 (1998-03-01), pages 609 - 615, XP008086243, ISSN: 0163-2116 *
MARSHALL J K ET AL: "Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance", CANADIAN JOURNAL OF GASTROENTEROLOGY, MEDICARE PUBL., OAKVILLE, CA, vol. 12, no. 4, 1998, pages 273 - 275, XP008086245, ISSN: 0835-7900 *
MATSUMURA ET AL: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast", MEDLINE, 23 February 1999 (1999-02-23), XP002953929 *
MINOCHA A ET AL: "Role of ketotifen in pathogenesis of chronic ulcerative colitis", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 104, no. 4 SUPPL, 1993, pages A746, XP008086242, ISSN: 0016-5085 *
NOBUHIDE O ET AL: "Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 56, no. 4, April 2007 (2007-04-01), pages 599 - 600, XP008086231, ISSN: 0017-5749 *
SAIURA A ET AL: "Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 433, no. 2-3, 21 December 2001 (2001-12-21), pages 163 - 168, XP008086230, ISSN: 0014-2999 *
SHIMIZU T ET AL: "INHIBITORY EFFECTS OF AZELASTINE AND TRANILAST ON LEUKOTRIENE B4 AND LEUKOTRIENE C4, GENERATION BY RAT COLONIC MUCOSA", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 53, no. 5, 1995, pages 355 - 358, XP001042184, ISSN: 0952-3278 *
STILLER-MATULA J ET AL: "Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 97, no. 3, March 2007 (2007-03-01), pages 385 - 393, XP008086107, ISSN: 0340-6245 *
SUWAKI T ET AL: "Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 12, November 2001 (2001-11-01), pages 2163 - 2171, XP002443957, ISSN: 1567-5769 *
TAMAOKI JUN: "Role of a Th2 cytokine inhibitor in asthma treatment", ALLERGOLOGY INTERNATIONAL, BLACKWELL SCIENCE, CARLTON,, AU, vol. 53, no. 2, June 2004 (2004-06-01), pages 55 - 60, XP002443956, ISSN: 1323-8930 *
TEH L G ET AL: "Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis?", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 17, no. 2, 1984, pages 157 - 159, XP008086082, ISSN: 0306-5251 *
WALLENTIN L C ET AL: "Prasugrel (CS-747), a novel thienopyridine P2Y12 receptor antagonist, results in more effective platelet inhibition than clopidogrel in aspirin-treated patients with atherosclerotic disease", EUROPEAN HEART JOURNAL, THE EUROPEAN SOCIETY OF CARDIOLOGY, XX, vol. 26, no. Suppl1, 6 September 2005 (2005-09-06), pages 488, XP008086116, ISSN: 0195-668X *
YAMADA N ET AL: "MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 6, 25 September 1992 (1992-09-25), pages 1211 - 1213, XP023732179, ISSN: 0006-2952, [retrieved on 19920925] *
YANAGIHARA Y ET AL: "Immunopharmacological studies on TBX, a new antiallergic drug. (4) Effects on type II to IV allergic reactions and immunological functions in animal models", JAPANESE JOURNAL OF PHARMACOLOGY, JPTHE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, vol. 51, no. 1, 1 January 1989 (1989-01-01), pages 93 - 100, XP008066536, ISSN: 0021-5198 *
ZHANG W ET AL: "Development of new therapeutic effect and mechanism of tranilast", ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, SHANGHAI SHI YIYAO GUANLIJU KE-JI QINGBAO YANJIUSUO ZHONGGUO, CN, vol. 23, no. 11, November 2004 (2004-11-01), pages 795 - 798, XP008086232, ISSN: 1007-7669 *

Also Published As

Publication number Publication date
WO2009007675A2 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2009007675A3 (fr) Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
WO2009007673A3 (fr) Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires
EP2497470B8 (fr) Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinase
WO2007052285A8 (fr) Systeme universel de gestion des connaissances et de recherche bureau
WO2008101682A3 (fr) Nouveaux microbiocides
IL173935A0 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
MX2009006507A (es) Nueva combinacion para usarse en el tratamiento de trastornos inflamatorios.
WO2009007679A3 (fr) Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
WO2009007674A3 (fr) Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
AU2003235122A1 (en) Cell death inhibitor
IL201168A0 (en) New combination for use in the treatment of inflammatory disorders
WO2009007680A3 (fr) Nouvelle combinaison destinée à être utilisée dans le traitement de troubles inflammatoires
IL195420A0 (en) Arylsulfonyl naphthalene derivatives and uses thereof
WO2007035964A3 (fr) Bioisoteres de la vigabatrine et methodes d'utilisation de ceux-ci
HK1114093A (en) Imidazolo-5-yl-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
HK1139146A (en) Heterocyclic compounds and use thereof as erk inhibitors
HK1115753A (en) Quinazolines and their use as aurora kinase inhibitors
HK1124334A (en) Diketo-piperazine and piperidine derivatives as antiviral agents
HK1126196A (en) 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation
HK1100928A (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
AU2005100796A4 (en) Hexagonal Rotating Pool Table
AU2006906244A0 (en) Water cooling equipment
HK1114765A (en) The preparation and use of compounds as protease inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08762504

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762504

Country of ref document: EP

Kind code of ref document: A2